Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 12;22(6):2872.
doi: 10.3390/ijms22062872.

Therapeutic Potentials of Low-Dose Tacrolimus for Aberrant Endometrial Features in Polycystic Ovary Syndrome

Ahmad J H Albaghdadi  1 , Frederick W K Kan  1
Affiliations
Review

Therapeutic Potentials of Low-Dose Tacrolimus for Aberrant Endometrial Features in Polycystic Ovary Syndrome

Ahmad J H Albaghdadi et al. Int J Mol Sci. .

Abstract

Polycystic ovary syndrome (PCOS) is a major anovulatory infertility affecting a great proportion of women of childbearing age and is associated with obesity, insulin resistance and chronic inflammation. Poor endometrial receptivity and recurrent implantation failure are major hurdles to the establishment of pregnancy in women with PCOS. The accumulating body of evidence obtained from experimental and clinical studies suggests a link between inherent adaptive and innate immune irregularities and aberrant endometrial features in PCOS. The use of conventional therapeutic interventions such as lifestyle modification, metformin and ovarian stimulation has achieved limited clinical success in restoring ovulation and endometrial receptivity in women with PCOS. Unlike other immunosuppressive drugs prescribed in the clinical management of autoimmune and inflammatory disorders that may have deleterious effects on fertility and fetal development, preclinical studies in mice and in women without PCOS but with repeated implantation failure revealed potential therapeutic benefits for the use of low-dose tacrolimus in treating female infertility. Improved systemic and ovarian immune functions, endometrial progesterone receptor and coreceptor expressions and uterine vascular adaptation to pregnancy were among features of enhanced progesterone-receptor sensitivity in the low-dose tacrolimus-treated mouse model of the disease. In this review, we have compiled available experimental and clinical data in literature on endometrial progesterone resistance and current therapeutic options, as well as mechanisms of actions and reported outcomes relevant to the potential therapeutic benefits for the use of low-dose tacrolimus in treating PCOS-associated female infertility.

Keywords: chronic inflammation; endometrial progesterone resistance; immunosuppression; polycystic ovary syndrome (PCOS); tacrolimus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mohammad M.B., Seghinsara A.M. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pac. J. Cancer Prev. 2017;18:17–21. doi: 10.22034/APJCP.2017.18.1.17. - DOI - PMC - PubMed
    1. Zangeneh F.Z., Naghizadeh M.M., Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int. J. Reprod. Biomed. 2017;15:375–382. doi: 10.29252/ijrm.15.6.375. - DOI - PMC - PubMed
    1. Wang L., Qi H., Baker P.N., Zhen Q., Zeng Q., Shi R., Tong C., Ge Q. Altered Circulating Inflammatory Cytokines Are Associated with Anovulatory Polycystic Ovary Syndrome (PCOS) Women Resistant to Clomiphene Citrate Treatment. Med. Sci. Monit. 2017;23:1083–1089. doi: 10.12659/MSM.901194. - DOI - PMC - PubMed
    1. Boots C.E., Jungheim E.S. Inflammation and Human Ovarian Follicular Dynamics. Semin. Reprod. Med. 2015;33:270–275. doi: 10.1055/s-0035-1554928. - DOI - PMC - PubMed
    1. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K., Endocrine S. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013;98:4565–4592. doi: 10.1210/jc.2013-2350. - DOI - PMC - PubMed

MeSH terms

Supplementary concepts